Bath Savings Trust Co Sells 3,308 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Bath Savings Trust Co reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15.2% during the fourth quarter, HoldingsChannel reports. The firm owned 18,506 shares of the company’s stock after selling 3,308 shares during the period. Bath Savings Trust Co’s holdings in IDEXX Laboratories were worth $7,651,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in IDXX. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. boosted its position in IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after buying an additional 57 shares during the period. Mowery & Schoenfeld Wealth Management LLC grew its position in shares of IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after buying an additional 60 shares during the last quarter. Ashton Thomas Securities LLC bought a new stake in IDEXX Laboratories in the third quarter valued at $37,000. Finally, Strategic Investment Solutions Inc. IL bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $36,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.11% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several analyst reports. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Barclays dropped their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Leerink Partners started coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, JPMorgan Chase & Co. decreased their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $539.63.

IDEXX Laboratories Price Performance

IDXX traded down $2.02 during trading hours on Tuesday, hitting $427.14. The company’s stock had a trading volume of 217,562 shares, compared to its average volume of 389,038. The business’s 50-day moving average price is $424.02 and its 200-day moving average price is $461.79. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The stock has a market cap of $34.98 billion, a price-to-earnings ratio of 41.19, a P/E/G ratio of 3.94 and a beta of 1.36. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. During the same quarter in the prior year, the firm posted $2.53 EPS. IDEXX Laboratories’s quarterly revenue was up 6.6% compared to the same quarter last year. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.